Since USFDA is aware of NDMA (N-Nitrosodimethylamine) is present as an impurity in some Ranitidine API and drugs products. FDA has issued a 'DMF information request' to M/s. SMS Pharmaceuticals Limited also to provide the information to demonstrate our Ranitidine API manufacturing process does not contain NDMA impurity.
The technical team is evaluating Ranitidine manufacturing process and will furnish the FDA requested data within the time frame set to us.
Shares of SMS PHARMACEUTICALS LTD. was last trading in BSE at Rs.48.05 as compared to the previous close of Rs. 50.05. The total number of shares traded during the day was 1128 in over 83 trades.
The stock hit an intraday high of Rs. 50 and intraday low of 48. The net turnover during the day was Rs. 54728.